Literature DB >> 4611771

Factor time for active immunotherapy after cytoreductive chemotherapy.

J L Amiel, M Berardet.   

Abstract

Mesh：

Substances：

Year:  1974        PMID： 4611771     DOI： 10.1016/0014-2964(74)90057-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.

Authors:  M A Schwarz; J U Gutterman; E M Hersh; S P Richman; G M Mavligit
Journal:  World J Surg       Date:  1977-09       Impact factor: 3.352

2.  Effect of intralesional and systemic BCG-application or a combined cyclophosphamide/BCG treatment on experimental bladder cancer.

Authors:  H D Adolphs; J Thiele; H Kiel
Journal:  Urol Res       Date:  1979-06-22

3.  Analysis of synergy between cyclophosphamide therapy and immunity against a mouse tumour.

Authors:  D M Chassoux; F M Gotch; I C MacLennan
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.